PubMed日本語 - ストレプトキナーゼは、心筋梗塞患者で線溶療法の後ジペプチジルペプチダーゼIV(CD26)自己抗体の発生を促進する。―QLifePro医療翻訳医療翻訳 QLifePro


Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.


Published date


Clin Diagn Lab Immunol. 2002; 9; 1253-9;


Miguel Cuchacovich, Héctor Gatica, Paula Vial, Jorge Yovanovich, Salvatore V Pizzo, Mario Gonzalez-Gronow


Rheumatology Section,University of Chile Clinical Hospital, Santiago, Chile.


Dipeptidyl peptidase IV (DPP IV) (CD26) plays a critical role in the modulation and expression of autoimmune and inflammatory diseases. We recently reported that sera from patients with rheumatoid arthritis and systemic lupus erythematosus contained low levels of DPP IV and high titers of anti-DPP IV autoantibodies of the immunoglobulin A (IgA) and IgG classes and found a correlation between the low circulating levels of DPP IV and the high titers of anti-DPP IV autoantibodies of the IgA class. Since streptokinase (SK) is a potent immunogen and binds to DPP IV, we speculated that patients with autoimmune diseases showed higher DPP IV autoantibody levels than healthy controls as a consequence of an abnormal immune stimulation triggered by SK released during streptococcal infections. We assessed this hypothesis in a group of patients suffering from acute myocardial infarction, without a chronic autoimmune disease, who received SK as part of therapeutic thrombolysis. Concomitant with the appearance of anti-SK antibodies, these patients developed anti-DPP IV autoantibodies. These autoantibodies bind to DPP IV in the region which is also recognized by SK, suggesting that an SK-induced immune response is responsible for the appearance of DPP IV autoantibodies. Furthermore, we determined a correlation between high titers of DPP IV autoantibodies and an augmented clearance of the enzyme from the circulation. Serum levels of the inflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) increased significantly after 30 days of SK administration, while the levels of soluble IL-2 receptor remained unchanged during the same period, suggesting a correlation between the lower levels of circulating DPP IV and higher levels of TNF-alpha and IL-6 in serum in these patients.


ストレプトキナーゼ(SK)が強力な免疫原で、静注でDPPと結合するので、我々は自己免疫疾患患者が異常な免疫刺激の結果として健常対照者が連鎖球菌性感染の間、リリースされるSKによって起動したより高いDPP IV自己抗体レベルを示すと推測した。
そして、SKによって誘発された免疫応答がDPP IV自己抗体の外観の原因となることを示唆する。
さらにまた、我々はDPP IV自己抗体の高い力価と血行からの酵素の増大された排除間の相関を決めた。

460万語の専門辞書を備えた医療者専用翻訳サービス QLifePro医療翻訳